Anticancer Res

• 

  Publication Venue For

  • Hospital Volume Threshold for the Treatment of Retroperitoneal Sarcoma..  39:2007-2014. 2019
  • Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma..  38:2875-2881. 2018
  • Update on Surgical Management of Small Bowel Neuroendocrine Tumors..  38:1267-1278. 2018
  • Neuroendocrine Neoplasms of the Appendix: A Review of the Literature..  38:601-611. 2018
  • Non-Whipple Operations in the Management of Benign, Premalignant and Early Cancerous Duodenal Lesions..  37:1443-1452. 2017
  • Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study..  37:719-725. 2017
  • Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response..  36:2639-2648. 2016
  • Risk Factors Associated with Disease Recurrence in Patients with Stage III/IV Squamous Cell Carcinoma of the Oral Cavity Treated with Surgery and Postoperative Radiotherapy..  36:785-792. 2016
  • The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma..  35:2465-2474. 2015
  • Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era..  34:2405-2411. 2014
  • c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival..  33:3241-3245. 2013
  • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer..  32:4963-4969. 2012
  • A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors..  32:1689-1696. 2012
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide..  31:4537-4543. 2011
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer..  31:1417-1420. 2011
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models..  30:5037-5042. 2010
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors..  30:1251-1256. 2010
  • A case of curative-intent hepatectomy for colon cancer metastatic to the scapula and liver..  30:677-679. 2010